The role of magnetic resonance imaging in cardio-oncology-Reference-Cited by-同舟云学术

The role of magnetic resonance imaging in cardio-oncology

Published:2024-06-14 Issue:2 Volume:4 Page:71-77
ISSN:2782-6171
Container-title:MD-Onco
language:
Short-container-title:jour

Author:

Ivanova Z. Z.¹^ORCID,Alexandrova S. A.¹^ORCID,Zeynalova P. A.²^ORCID,Akhobekov A. A.³^ORCID

Affiliation:

1. A.N. Bakulev National Medical Research Center for Cardiovascular Surgery, Ministry of Health of Russia

2. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

3. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Abstract

In recent decades, groundbreaking methods of diagnosis and treatment were developed leading to significantly increased life span of patients with malignant neoplasms. Among patients treated for cancer, cardiovascular diseases are the leading cause of death not associated with cancer. Early identification of cardiotoxicity is very important as it allows to apply early prevention measures and modify antitumor treatment schemes. Prevention and treatment of cardiotoxicity are possible only with a functioning multidisciplinary team including oncologists and cardiologists. Magnetic resonance imaging of the heart plays a significant role in monitoring the condition of cardiovascular system during antitumor treatment. This technique allows to obtain accurate characteristics of the tissues and evaluate myocardial perfusion without radiation exposure.

Publisher

Publishing House ABV Press

Reference29 articles.

1. Sturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. DOI: 10.1093/eurheartj/ehz766

2. Armstrong G.T., Liu Q., Yasui Y. et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27(14):2328–38. DOI: 10.1200/JCO.2008.21.1425

3. Plana J.C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. DOI: 10.1093/ehjci/jeu192

4. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211

5. Armenian S.H., Hudson M.M., Mulder R.L. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36. DOI: 10.1016/S1470-2045(14)70409-7